BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets. | BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to ...

Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) ...

BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment ...

WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary technology for use against multiple specific targets.

BioAtla, Inc. (NASDAQ: BCAB or the "Company"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsAlbert Bourla - Chairman of the Board ...

WuXi XDC inks collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform: Shanghai, China Monday, March 2, 2026, 17:00 Hrs [IST] WuXi XDC Cayman Inc. (WuXi ...

Biohaven Ltd. (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsAdam Lenkowsky - Executive ...

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM).

Q4 revenue -- $67.3 million reported for the quarter ended Dec. 31, 2025, compared to $1.5 million in Q4 2024; increase driven primarily by AstraZeneca and Gilead (NASDAQ:GILD) payments. Full-year ...

The Rev. Jesse Jackson Sr. is returning to South Carolina for a final public farewell. On Monday, Jackson will lie in state ...